Clinical trials: Pain Intensity
Osteoarthritis, Pain Intensity Assessment
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain
The purpose of this study is to evaluate the safety of CG5503 base Immediate Release(IR) 50 mg or 100 mg taken every 4 to 6 hours as needed over the long-term exposure of 90 days in patients who have chronic pain.
- Conditions
- Osteoarthritis, Pain Intensity Assessment, Arthralgia, Sciatica
- Trial name
- NCT00364546
- Testing
- CG 5503;tapentadol
- Volunteers
- 877 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.